Skip to content
Screener

Prime Medicine PRME Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$1.2MMiss by $1.1M
EPS-$0.24Beat by $0.02
Revenue estimate$2.3M
EPS estimate-$0.26

Next report

Nov 6, 2026 (in 2 months)
Revenue estimate$1.3M
EPS estimate-$0.23

Financials

Q2 2026

Income statement

See full
Operating income-$43.3M+18.9%
Net income-$42.1M+19.9%
EPS (diluted)-$0.24+41.5%

Balance sheet

See full
Cash & equivalents$61.1M-9.4%
Total debt$112.5M-6.1%
Total equity$39.8M-34.6%
Total assets$249.0M-10.7%

Cash flow

See full
Operating cash flow-$41.0M+0.9%
CapEx$46.0K-97.1%
Free cash flow-$41.1M+4.4%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$544.13M-34.4%
Enterprise value$595.47M-32.4%

Returns & leverage

See full
Return on equity-373.3%-1,281pp
Debt / equity2.8×+0.9×
Current ratio3.1×-0.5×

Segments

By segment

See full
Reportable Segment$1.2M+3.5%

FAQ

When did Prime Medicine report Q2 2026 earnings?
Prime Medicine (PRME) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Prime Medicine's Q2 2026 revenue and EPS?
Prime Medicine reported revenue of $1.2M and eps of $-0.24 for Q2 2026.
Did Prime Medicine beat estimates in Q2 2026?
Revenue missed the consensus estimate of $2.3M by $1.1M. EPS beat the consensus estimate of $-0.26 by $0.02.
How did Prime Medicine's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 3.5% from $1.1M a year earlier and eps grew 41.5% from $-0.41.
Where can I find Prime Medicine's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-053878) and the 10-Q periodic report (0001628280-26-053883) directly on SEC EDGAR. The filing index links above go to sec.gov.